Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Cash (2020 - 2025)

Tango Therapeutics has reported Change in Cash over the past 6 years, most recently at $53.9 million for Q4 2025.

  • Quarterly results put Change in Cash at $53.9 million for Q4 2025, up 229.27% from a year ago — trailing twelve months through Dec 2025 was $42.7 million (up 1767.58% YoY), and the annual figure for FY2025 was $42.7 million, up 1767.58%.
  • Change in Cash for Q4 2025 was $53.9 million at Tango Therapeutics, up from $19.1 million in the prior quarter.
  • Over the last five years, Change in Cash for TNGX hit a ceiling of $154.1 million in Q3 2021 and a floor of -$62.2 million in Q4 2021.
  • Median Change in Cash over the past 5 years was -$3.8 million (2022), compared with a mean of $4.2 million.
  • Peak annual rise in Change in Cash hit 9825.87% in 2021, while the deepest fall reached 59672.68% in 2021.
  • Tango Therapeutics' Change in Cash stood at -$62.2 million in 2021, then skyrocketed by 35.17% to -$40.3 million in 2022, then surged by 119.46% to $7.9 million in 2023, then surged by 108.63% to $16.4 million in 2024, then soared by 229.27% to $53.9 million in 2025.
  • The last three reported values for Change in Cash were $53.9 million (Q4 2025), $19.1 million (Q3 2025), and -$19.2 million (Q2 2025) per Business Quant data.